Immuno-Oncology News’ Ines Martins reports Merck KGaA (operating as EMD Serono in the U.S.) and Pfizer’s jointly developed immune checkpoint inhibitor Bavencio (avelumab) shows durable clinical activity and long-term disease control among heavily pretreated malignant...